nach oben

Heart Failure Reviews

Erschienen in:

01.08.2016

The evolving role of adiponectin as an additive biomarker in HFrEF

verfasst von: Tahnee Sente, Andreas Gevaert, An Van Berendoncks, Christiaan J. Vrints, Vicky Y. Hoymans

Erschienen in: Heart Failure Reviews | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Heart failure (HF) is a growing health problem. Despite improved management and outcome, the number of patients with HF is expected to keep rising in the following years. In recent research, adiponectin was shown to exert beneficial effects in the cardiovascular system, but the protein was also implicated in the development and progression of HF. The objective of this review is to provide an overview of current knowledge on the role of adiponectin in HF with reduced ejection fraction. We discuss the cardioprotective and (anti-) inflammatory actions of adiponectin and its potential use in clinical diagnosis and prognosis.

Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Stafford R, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J, American Heart Association Statistics C, Stroke Statistics S (2010) Executive summary: heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation 121(7):948–954. doi:10.1161/CIRCULATIONAHA.109.192666 PubMedCrossRef

Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, Meverden RA, Roger VL (2006) Systolic and diastolic heart failure in the community. JAMA 296(18):2209–2216. doi:10.1001/jama.296.18.2209 PubMedCrossRef

Bui AL, Horwich TB, Fonarow GC (2011) Epidemiology and risk profile of heart failure. Nat Rev Cardiol 8(1):30–41. doi:10.1038/nrcardio.2010.165 PubMedCrossRef

Warriner D, Sheridan P, Lawford P (2015) Heart failure: not a single organ disease but a multisystem syndrome. Br J Hosp Med 76(6):330–336. doi:10.12968/hmed.2015.76.6.330 CrossRef

Joosten MM, Joshipura KJ, Pai JK, Bertoia ML, Rimm EB, Mittleman MA, Mukamal KJ (2013) Total adiponectin and risk of symptomatic lower extremity peripheral artery disease in men. Arterioscler Thromb Vasc Biol 33(5):1092–1097. doi:10.1161/ATVBAHA.112.301089 PubMedPubMedCentralCrossRef

Sook Lee E, Park SS, Kim E, Sook Yoon Y, Ahn HY, Park CY, Ho Yun Y, Woo OhS (2013) Association between adiponectin levels and coronary heart disease and mortality: a systematic review and meta-analysis. Int J Epidemiol 42(4):1029–1039. doi:10.1093/ije/dyt087 PubMedCrossRef

Shibata R, Ouchi N, Murohara T (2009) Adiponectin and cardiovascular disease. Circ J 73(4):608–614PubMedCrossRef

Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y (2000) Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102(11):1296–1301PubMedCrossRef

Ouedraogo R, Wu X, Xu SQ, Fuchsel L, Motoshima H, Mahadev K, Hough K, Scalia R, Goldstein BJ (2006) Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway. Diabetes 55(6):1840–1846. doi:10.2337/db05-1174 PubMedCrossRef

10.

Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA, Lopez BL, Koch W, Chan L, Goldstein BJ, Ma XL (2007) Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 115(11):1408–1416. doi:10.1161/CIRCULATIONAHA.106.666941 PubMedCrossRef

11.

Frystyk J, Berne C, Berglund L, Jensevik K, Flyvbjerg A, Zethelius B (2007) Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab 92(2):571–576. doi:10.1210/jc.2006-1067 PubMedCrossRef

12.

Haugen E, Furukawa Y, Isic A, Fu M (2008) Increased adiponectin level in parallel with increased NT-pro BNP in patients with severe heart failure in the elderly: a hospital cohort study. Int J Cardiol 125(2):216–219. doi:10.1016/j.ijcard.2007.12.002 PubMedCrossRef

13.

Nakamura T, Funayama H, Kubo N, Yasu T, Kawakami M, Saito M, Momomura S, Ishikawa SE (2006) Association of hyperadiponectinemia with severity of ventricular dysfunction in congestive heart failure. Circ J 70(12):1557–1562PubMedCrossRef

14.

Sokhanvar S, Sheykhi M, Mazlomzade S, Taran L, Golmohammadi Z (2013) The relationship between serum adiponectin and prognosis in patients with heart failure. Bratisl Lek Listy 114(8):455–459PubMed

15.

Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270(45):26746–26749PubMedCrossRef

16.

Shapiro L, Scherer PE (1998) The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 8(6):335–338PubMedCrossRef

17.

Fang X, Sweeney G (2006) Mechanisms regulating energy metabolism by adiponectin in obesity and diabetes. Biochem Soc Trans 34(Pt 5):798–801. doi:10.1042/BST0340798 PubMedCrossRef

18.

Yamauchi T, Kadowaki T (2008) Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes 32(Suppl 7):S13–S18. doi:10.1038/ijo.2008.233 CrossRef

19.

Tsao TS, Tomas E, Murrey HE, Hug C, Lee DH, Ruderman NB, Heuser JE, Lodish HF (2003) Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J Biol Chem 278(50):50810–50817. doi:10.1074/jbc.M309469200 PubMedCrossRef

20.

Waki H, Yamauchi T, Kamon J, Kita S, Ito Y, Hada Y, Uchida S, Tsuchida A, Takekawa S, Kadowaki T (2005) Generation of globular fragment of adiponectin by leukocyte elastase secreted by monocytic cell line THP-1. Endocrinology 146(2):790–796. doi:10.1210/en.2004-1096 PubMedCrossRef

21.

Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takayanagi K, Takebayashi K, Okuno T, Inoue T, Node K, Tobe T, Inukai T, Nakano Y (2006) Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 55(7):1954–1960. doi:10.2337/db05-1525 PubMedCrossRef

22.

Fisher FM, Trujillo ME, Hanif W, Barnett AH, McTernan PG, Scherer PE, Kumar S (2005) Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. Diabetologia 48(6):1084–1087. doi:10.1007/s00125-005-1758-7 PubMedCrossRef

23.

Nanayakkara G, Kariharan T, Wang L, Zhong J, Amin R (2012) The cardio-protective signaling and mechanisms of adiponectin. Am J Cardiovasc Dis 2(4):253–266PubMedPubMedCentral

24.

Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE (2004) Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279(13):12152–12162. doi:10.1074/jbc.M311113200 PubMedCrossRef

25.

Heidemann C, Sun Q, van Dam RM, Meigs JB, Zhang C, Tworoger SS, Mantzoros CS, Hu FB (2008) Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med 149(5):307–316PubMedPubMedCentralCrossRef

26.

Combs TP, Berg AH, Rajala MW, Klebanov S, Iyengar P, Jimenez-Chillaron JC, Patti ME, Klein SL, Weinstein RS, Scherer PE (2003) Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes 52(2):268–276PubMedCrossRef

27.

Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y (2002) Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51(9):2734–2741PubMedCrossRef

28.

Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G (2003) Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 52(7):1779–1785PubMedCrossRef

29.

Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, Drevon CA, Syversen U, Reseland JE (2004) Adiponectin and its receptors are expressed in bone-forming cells. Bone 35(4):842–849. doi:10.1016/j.bone.2004.06.008 PubMedCrossRef

30.

Delaigle AM, Jonas JC, Bauche IB, Cornu O, Brichard SM (2004) Induction of adiponectin in skeletal muscle by inflammatory cytokines: in vivo and in vitro studies. Endocrinology 145(12):5589–5597. doi:10.1210/en.2004-0503 PubMedCrossRef

31.

Krause MP, Liu Y, Vu V, Chan L, Xu A, Riddell MC, Sweeney G, Hawke TJ (2008) Adiponectin is expressed by skeletal muscle fibers and influences muscle phenotype and function. Am J Physiol Cell Physiol 295(1):C203–C212. doi:10.1152/ajpcell.00030.2008 PubMedPubMedCentralCrossRef

32.

Kadowaki T, Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 26(3):439–451. doi:10.1210/er.2005-0005 PubMedCrossRef

33.

Ouchi N, Walsh K (2007) Adiponectin as an anti-inflammatory factor. Clin Chim Acta 380(1–2):24–30. doi:10.1016/j.cca.2007.01.026 PubMedPubMedCentralCrossRef

34.

Shinmura K (2010) Is adiponectin a bystander or a mediator in heart failure? the tangled thread of a good-natured adipokine in aging and cardiovascular disease. Heart Fail Rev 15(5):457–466. doi:10.1007/s10741-010-9159-5 PubMedCrossRef

35.

Tsubakio-Yamamoto K, Matsuura F, Koseki M, Oku H, Sandoval JC, Inagaki M, Nakatani K, Nakaoka H, Kawase R, Yuasa-Kawase M, Masuda D, Ohama T, Maeda N, Nakagawa-Toyama Y, Ishigami M, Nishida M, Kihara S, Shimomura I, Yamashita S (2008) Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages. Biochem Biophys Res Commun 375(3):390–394. doi:10.1016/j.bbrc.2008.08.009 PubMedCrossRef

36.

Karbowska J, Kochan Z (2006) Role of adiponectin in the regulation of carbohydrate and lipid metabolism. J Physiol Pharmacol 57(Suppl 6):103–113PubMed

37.

Shibata R, Skurk C, Ouchi N, Galasso G, Kondo K, Ohashi T, Shimano M, Kihara S, Murohara T, Walsh K (2008) Adiponectin promotes endothelial progenitor cell number and function. FEBS Lett 582(11):1607–1612. doi:10.1016/j.febslet.2008.04.006 PubMedPubMedCentralCrossRef

38.

Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423(6941):762–769. doi:10.1038/nature01705 PubMedCrossRef

39.

Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu M, Kawamoto S, Kubota N, Kubota T, Ito Y, Kamon J, Tsuchida A, Kumagai K, Kozono H, Hada Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Awazawa M, Takamoto I, Froguel P, Hara K, Tobe K, Nagai R, Ueki K, Kadowaki T (2007) Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13(3):332–339. doi:10.1038/nm1557 PubMedCrossRef

40.

Yamauchi T, Iwabu M, Okada-Iwabu M, Kadowaki T (2014) Adiponectin receptors: a review of their structure, function and how they work. Best Pract Res Clin Endocrinol Metab 28(1):15–23. doi:10.1016/j.beem.2013.09.003 PubMedCrossRef

41.

Tanabe H, Fujii Y, Okada-Iwabu M, Iwabu M, Nakamura Y, Hosaka T, Motoyama K, Ikeda M, Wakiyama M, Terada T, Ohsawa N, Hato M, Ogasawara S, Hino T, Murata T, Iwata S, Hirata K, Kawano Y, Yamamoto M, Kimura-Someya T, Shirouzu M, Yamauchi T, Kadowaki T, Yokoyama S (2015) Crystal structures of the human adiponectin receptors. Nature 520(7547):312–316. doi:10.1038/nature14301 PubMedPubMedCentralCrossRef

42.

Yamaguchi N, Argueta JG, Masuhiro Y, Kagishita M, Nonaka K, Saito T, Hanazawa S, Yamashita Y (2005) Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett 579(30):6821–6826. doi:10.1016/j.febslet.2005.11.019 PubMedCrossRef

43.

Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8(11):1288–1295. doi:10.1038/nm788 PubMedCrossRef

44.

Yoon MJ, Lee GY, Chung JJ, Ahn YH, Hong SH, Kim JB (2006) Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes 55(9):2562–2570. doi:10.2337/db05-1322 PubMedCrossRef

45.

Cheng KK, Lam KS, Wang Y, Huang Y, Carling D, Wu D, Wong C, Xu A (2007) Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes 56(5):1387–1394. doi:10.2337/db06-1580 PubMedCrossRef

46.

Mao X, Kikani CK, Riojas RA, Langlais P, Wang L, Ramos FJ, Fang Q, Christ-Roberts CY, Hong JY, Kim RY, Liu F, Dong LQ (2006) APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol 8(5):516–523. doi:10.1038/ncb1404 PubMedCrossRef

47.

Deepa SS, Dong LQ (2009) APPL1: role in adiponectin signaling and beyond. Am J Physiol Endocrinol Metab 296(1):E22–E36. doi:10.1152/ajpendo.90731.2008 PubMedCrossRef

48.

Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF (2004) T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA 101(28):10308–10313. doi:10.1073/pnas.0403382101 PubMedPubMedCentralCrossRef

49.

Denzel MS, Scimia MC, Zumstein PM, Walsh K, Ruiz-Lozano P, Ranscht B (2010) T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Investig 120(12):4342–4352. doi:10.1172/JCI43464 PubMedPubMedCentralCrossRef

50.

Motoshima H, Wu X, Mahadev K, Goldstein BJ (2004) Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun 315(2):264–271. doi:10.1016/j.bbrc.2004.01.049 PubMedCrossRef

51.

Tao L, Wang Y, Gao E, Zhang H, Yuan Y, Lau WB, Chan L, Koch WJ, Ma XL (2010) Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction. Circ Res 106(2):409–417. doi:10.1161/CIRCRESAHA.109.211797 PubMedCrossRef

52.

Goldstein BJ, Scalia RG, Ma XL (2009) Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med 6(1):27–35. doi:10.1038/ncpcardio1398 PubMedCrossRef

53.

Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A (2008) Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci 114(5):361–374. doi:10.1042/CS20070347 PubMedCrossRef

54.

Jahng JW, Turdi S, Kovacevic V, Dadson K, Li RK, Sweeney G (2015) Pressure overload-induced cardiac dysfunction in aged male adiponectin knockout mice is associated with autophagy deficiency. Endocrinology 156(7):2667–2677. doi:10.1210/en.2015-1162 PubMedCrossRef

55.

Liao Y, Takashima S, Maeda N, Ouchi N, Komamura K, Shimomura I, Hori M, Matsuzawa Y, Funahashi T, Kitakaze M (2005) Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res 67(4):705–713. doi:10.1016/j.cardiores.2005.04.018 PubMedCrossRef

56.

O’Shea KM, Chess DJ, Khairallah RJ, Rastogi S, Hecker PA, Sabbah HN, Walsh K, Stanley WC (2010) Effects of adiponectin deficiency on structural and metabolic remodeling in mice subjected to pressure overload. Am J Physiol Heart Circ Physiol 298(6):H1639–H1645. doi:10.1152/ajpheart.00957.2009 PubMedPubMedCentralCrossRef

57.

Shimano M, Ouchi N, Shibata R, Ohashi K, Pimentel DR, Murohara T, Walsh K (2010) Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response. J Mol Cell Cardiol 49(2):210–220. doi:10.1016/j.yjmcc.2010.02.021 PubMedPubMedCentralCrossRef

58.

Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, Ohashi K, Sakai N, Shimomura I, Kobayashi H, Terasaka N, Inaba T, Funahashi T, Matsuzawa Y (2002) Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106(22):2767–2770PubMedCrossRef

59.

Kato H, Kashiwagi H, Shiraga M, Tadokoro S, Kamae T, Ujiie H, Honda S, Miyata S, Ijiri Y, Yamamoto J, Maeda N, Funahashi T, Kurata Y, Shimomura I, Tomiyama Y, Kanakura Y (2006) Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol 26(1):224–230. doi:10.1161/01.ATV.0000194076.84568.81 PubMedCrossRef

60.

Kondo K, Shibata R, Unno K, Shimano M, Ishii M, Kito T, Shintani S, Walsh K, Ouchi N, Murohara T (2010) Impact of a single intracoronary administration of adiponectin on myocardial ischemia/reperfusion injury in a pig model. Circ Cardiovasc Intervent 3(2):166–173. doi:10.1161/CIRCINTERVENTIONS.109.872044 CrossRef

61.

Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, Funahashi T, Ouchi N, Walsh K (2005) Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 11(10):1096–1103. doi:10.1038/nm1295 PubMedPubMedCentralCrossRef

62.

Kojima S, Kojima S, Maruyoshi H, Nagayoshi Y, Kaikita K, Sumida H, Sugiyama S, Funahashi T, Ogawa H (2011) Hypercholesterolemia and hypoadiponectinemia are associated with necrotic core-rich coronary plaque. Int J Cardiol 147(3):371–376. doi:10.1016/j.ijcard.2009.09.536 PubMedCrossRef

63.

Sawada T, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, Kawamori H, Kato H, Miyoshi N, Yoshino N, Kozuki A, Hirata K (2010) Low plasma adiponectin levels are associated with presence of thin-cap fibroatheroma in men with stable coronary artery disease. Int J Cardiol 142(3):250–256. doi:10.1016/j.ijcard.2008.12.216 PubMedCrossRef

64.

Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N, Kumada M, Okamoto Y, Nagaretani H, Nishizawa H, Kishida K, Komuro R, Ouchi N, Kihara S, Nagai R, Funahashi T, Matsuzawa Y (2002) Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277(40):37487–37491. doi:10.1074/jbc.M206083200 PubMedCrossRef

65.

Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, Uchida S, Ito Y, Takakuwa K, Matsui J, Takata M, Eto K, Terauchi Y, Komeda K, Tsunoda M, Murakami K, Ohnishi Y, Naitoh T, Yamamura K, Ueyama Y, Froguel P, Kimura S, Nagai R, Kadowaki T (2003) Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278(4):2461–2468. doi:10.1074/jbc.M209033200 PubMedCrossRef

66.

Xu A, Wang Y, Lam KS, Vanhoutte PM (2010) Vascular actions of adipokines molecular mechanisms and therapeutic implications. Adv Pharmacol 60:229–255. doi:10.1016/B978-0-12-385061-4.00008-8 PubMedCrossRef

67.

Ohashi K, Ouchi N, Sato K, Higuchi A, Ishikawa TO, Herschman HR, Kihara S, Walsh K (2009) Adiponectin promotes revascularization of ischemic muscle through a cyclooxygenase 2-dependent mechanism. Mol Cell Biol 29(13):3487–3499. doi:10.1128/MCB.00126-09 PubMedPubMedCentralCrossRef

68.

Joshi MB, Philippova M, Ivanov D, Allenspach R, Erne P, Resink TJ (2005) T-cadherin protects endothelial cells from oxidative stress-induced apoptosis. FASEB J 19(12):1737–1739. doi:10.1096/fj.05-3834fje PubMed

69.

George J, Patal S, Wexler D, Sharabi Y, Peleg E, Kamari Y, Grossman E, Sheps D, Keren G, Roth A (2006) Circulating adiponectin concentrations in patients with congestive heart failure. Heart 92(10):1420–1424. doi:10.1136/hrt.2005.083345 PubMedPubMedCentralCrossRef

70.

Hopkins TA, Ouchi N, Shibata R, Walsh K (2007) Adiponectin actions in the cardiovascular system. Cardiovasc Res 74(1):11–18. doi:10.1016/j.cardiores.2006.10.009 PubMedCrossRef

71.

Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, Hildebrandt P (2005) Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112(12):1756–1762. doi:10.1161/CIRCULATIONAHA.104.530972 PubMedCrossRef

72.

Tsutamoto T, Tanaka T, Sakai H, Ishikawa C, Fujii M, Yamamoto T, Horie M (2007) Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 28(14):1723–1730. doi:10.1093/eurheartj/ehm154 PubMedCrossRef

73.

Norrelund H, Wiggers H, Halbirk M, Frystyk J, Flyvbjerg A, Botker HE, Schmitz O, Jorgensen JO, Christiansen JS, Moller N (2006) Abnormalities of whole body protein turnover, muscle metabolism and levels of metabolic hormones in patients with chronic heart failure. J Intern Med 260(1):11–21. doi:10.1111/j.1365-2796.2006.01663.x PubMedCrossRef

74.

Van Berendoncks AM, Garnier A, Beckers P, Hoymans VY, Possemiers N, Fortin D, Martinet W, Van Hoof V, Vrints CJ, Ventura-Clapier R, Conraads VM (2010) Functional adiponectin resistance at the level of the skeletal muscle in mild to moderate chronic heart failure. Circ Heart Fail 3(2):185–194. doi:10.1161/CIRCHEARTFAILURE.109.885525 PubMedCrossRef

75.

Beatty AL, Zhang MH, Ku IA, Na B, Schiller NB, Whooley MA (2012) Adiponectin is associated with increased mortality and heart failure in patients with stable ischemic heart disease: data from the Heart and Soul Study. Atherosclerosis 220(2):587–592. doi:10.1016/j.atherosclerosis.2011.11.038 PubMedCrossRef

76.

Baldasseroni S, Mannucci E, Orso F, Di Serio C, Pratesi A, Bartoli N, Marella GA, Colombi C, Foschini A, Valoti P, Mossello E, Fumagalli S, Marchionni N, Tarantini F (2012) Adiponectin in outpatients with coronary artery disease: independent predictors and relationship with heart failure. Nutr Metab Cardiovasc Dis 22(3):292–299. doi:10.1016/j.numecd.2011.03.012 PubMedCrossRef

77.

Ohara T, Hashimura K, Asakura M, Ogai A, Amaki M, Hasegawa T, Kanzaki H, Sonoda M, Nishizawa H, Funahashi T, Kitakaze M (2011) Dynamic changes in plasma total and high molecular weight adiponectin levels in acute heart failure. J Cardiol 58(2):181–190. doi:10.1016/j.jjcc.2011.06.010 PubMedCrossRef

78.

Gustafsson S, Lind L, Zethelius B, Venge P, Flyvbjerg A, Soderberg S, Ingelsson E (2010) Adiponectin and cardiac geometry and function in elderly: results from two community-based cohort studies. Eur J Endocrinol 162(3):543–550. doi:10.1530/EJE-09-1006 PubMedCrossRef

79.

Kung T, Szabo T, Springer J, Doehner W, Anker SD, von Haehling S (2011) Cachexia in heart disease: highlights from the ESC 2010. J Cachexia Sarcopenia Muscle 2(1):63–69. doi:10.1007/s13539-011-0020-z PubMedPubMedCentralCrossRef

80.

Lee Y, Kim BK, Lim YH, Kim MK, Choi BY, Shin J (2013) The relationship between adiponectin and left ventricular mass index varies with the risk of left ventricular hypertrophy. PLoS ONE 8(7):e70246. doi:10.1371/journal.pone.0070246 PubMedPubMedCentralCrossRef

81.

Sam F, Walsh K (2010) What can adiponectin say about left ventricular function? Heart 96(5):331–332. doi:10.1136/hrt.2009.178590 PubMedCrossRef

82.

Ebert T, Fasshauer M (2011) Adiponectin: sometimes good, sometimes bad? Cardiology 118(4):236–237. doi:10.1159/000329647 PubMedCrossRef

83.

Sente T, Van Berendoncks AM, Hoymans VY, Vrints CJ (2015) Adiponectin resistance in skeletal muscle: pathophysiological implications in chronic heart failure. J Cachexia Sarcopenia Muscle. doi:10.1002/jcsm.12086 PubMedPubMedCentral

84.

Hashimoto N, Kanda J, Nakamura T, Horie A, Kurosawa H, Hashimoto T, Sato K, Kushida S, Suzuki M, Yano S, Iwai R, Takahashi H, Yoshida S (2006) Association of hypoadiponectinemia in men with early onset of coronary heart disease and multiple coronary artery stenoses. Metab, Clin Exp 55(12):1653–1657. doi:10.1016/j.metabol.2006.08.005 CrossRef

85.

Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K, Fu Y, Motone M, Yamamoto K, Matsuo A, Ohashi K, Kihara S, Funahashi T, Rakugi H, Matsuzawa Y, Ogihara T (2004) Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43(6):1318–1323. doi:10.1161/01.HYP.0000129281.03801.4b PubMedCrossRef

86.

Lindberg S, Pedersen SH, Mogelvang R, Bjerre M, Frystyk J, Flyvbjerg A, Galatius S, Jensen JS (2012) Usefulness of adiponectin as a predictor of all cause mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol 109(4):492–496. doi:10.1016/j.amjcard.2011.09.041 PubMedCrossRef

87.

Won H, Kang SM, Shin MJ, Oh J, Hong N, Park S, Lee SH, Jang Y, Chung N (2012) Plasma adiponectin concentration and its association with metabolic syndrome in patients with heart failure. Yonsei Med J 53(1):91–98. doi:10.3349/ymj.2012.53.1.91 PubMedCrossRef

88.

Li S, Shin HJ, Ding EL, van Dam RM (2009) Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 302(2):179–188. doi:10.1001/jama.2009.976 PubMedCrossRef

89.

Okamoto H (2009) Can adiponectin be a novel metabolic biomarker for heart failure? Circ J 73(6):1012–1013PubMedCrossRef

90.

Yamaji M, Tsutamoto T, Tanaka T, Kawahara C, Nishiyama K, Yamamoto T, Fujii M, Horie M (2009) Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure. Circ J 73(6):1067–1073PubMedCrossRef

91.

Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291(14):1730–1737. doi:10.1001/jama.291.14.1730 PubMedCrossRef

92.

Kawano T, Saito T, Yasu T, Saito T, Nakamura T, Namai K, Tamemoto H, Kawakami M, Saito M, Ishikawa SE (2005) Close association of hypoadiponectinemia with arteriosclerosis obliterans and ischemic heart disease. Metab, Clin Exp 54(5):653–656. doi:10.1016/j.metabol.2004.12.009 CrossRef

93.

Djousse L, Wilk JB, Hanson NQ, Glynn RJ, Tsai MY, Gaziano JM (2013) Association between adiponectin and heart failure risk in the physicians’ health study. Obesity 21(4):831–834. doi:10.1002/oby.20260 PubMedPubMedCentralCrossRef

94.

Shibata R, Izumiya Y, Sato K, Papanicolaou K, Kihara S, Colucci WS, Sam F, Ouchi N, Walsh K (2007) Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J Mol Cell Cardiol 42(6):1065–1074. doi:10.1016/j.yjmcc.2007.03.808 PubMedPubMedCentralCrossRef

95.

Kizer JR, Arnold AM, Jenny NS, Cushman M, Strotmeyer ES, Ives DG, Ding J, Kritchevsky SB, Chaves PH, Hirsch CH, Newman AB (2011) Longitudinal changes in adiponectin and inflammatory markers and relation to survival in the oldest old: the Cardiovascular Health Study All Stars study. J Gerontol A Biol Sci Med Sci 66(10):1100–1107. doi:10.1093/gerona/glr098 PubMedCrossRef

96.

Kizer JR, Benkeser D, Arnold AM, Mukamal KJ, Ix JH, Zieman SJ, Siscovick DS, Tracy RP, Mantzoros CS, Defilippi CR, Newman AB, Djousse L (2012) Associations of total and high-molecular-weight adiponectin with all-cause and cardiovascular mortality in older persons: the Cardiovascular Health Study. Circulation 126(25):2951–2961. doi:10.1161/CIRCULATIONAHA.112.135202 PubMedPubMedCentralCrossRef

97.

Macheret F, Bartz TM, Djousse L, Ix JH, Mukamal KJ, Zieman SJ, Siscovick DS, Tracy RP, Heckbert SR, Psaty BM, Kizer JR (2015) Higher circulating adiponectin levels are associated with increased risk of atrial fibrillation in older adults. Heart 101(17):1368–1374. doi:10.1136/heartjnl-2014-307015 PubMedCrossRef

98.

Kizer JR, Arnold AM, Benkeser D, Ix JH, Djousse L, Zieman SJ, Barzilay JI, Tracy RP, Mantzoros CS, Siscovick DS, Mukamal KJ (2012) Total and high-molecular-weight adiponectin and risk of incident diabetes in older people. Diabetes Care 35(2):415–423. doi:10.2337/dc11-1519 PubMedPubMedCentralCrossRef

99.

Park M, Sweeney G (2013) Direct effects of adipokines on the heart: focus on adiponectin. Heart Fail Rev 18(5):631–644. doi:10.1007/s10741-012-9337-8 PubMedCrossRef

100.

Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y (1999) Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100(25):2473–2476PubMedCrossRef

101.

Pineiro R, Iglesias MJ, Gallego R, Raghay K, Eiras S, Rubio J, Dieguez C, Gualillo O, Gonzalez-Juanatey JR, Lago F (2005) Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett 579(23):5163–5169. doi:10.1016/j.febslet.2005.07.098 PubMedCrossRef

102.

Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y (2000) Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96(5):1723–1732PubMed

103.

Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y (2003) Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107(5):671–674PubMedCrossRef

104.

Devaraj S, Torok N, Dasu MR, Samols D, Jialal I (2008) Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop. Arterioscler Thromb Vasc Biol 28(7):1368–1374. doi:10.1161/ATVBAHA.108.163303 PubMedPubMedCentralCrossRef

105.

Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, Davis KE, Bikman BT, Halberg N, Rutkowski JM, Wade MR, Tenorio VM, Kuo MS, Brozinick JT, Zhang BB, Birnbaum MJ, Summers SA, Scherer PE (2011) Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 17(1):55–63. doi:10.1038/nm.2277 PubMedCrossRef

106.

Essick EE, Wilson RM, Pimentel DR, Shimano M, Baid S, Ouchi N, Sam F (2013) Adiponectin modulates oxidative stress-induced autophagy in cardiomyocytes. PLoS ONE 8(7):e68697. doi:10.1371/journal.pone.0068697 PubMedPubMedCentralCrossRef

107.

Park M, Youn B, Zheng XL, Wu D, Xu A, Sweeney G (2011) Globular adiponectin, acting via AdipoR1/APPL1, protects H9c2 cells from hypoxia/reoxygenation-induced apoptosis. PLoS ONE 6(4):e19143. doi:10.1371/journal.pone.0019143 PubMedPubMedCentralCrossRef

108.

Tsatsanis C, Zacharioudaki V, Androulidaki A, Dermitzaki E, Charalampopoulos I, Minas V, Gravanis A, Margioris AN (2005) Adiponectin induces TNF-alpha and IL-6 in macrophages and promotes tolerance to itself and other pro-inflammatory stimuli. Biochem Biophys Res Commun 335(4):1254–1263. doi:10.1016/j.bbrc.2005.07.197 PubMedCrossRef

109.

Savill J, Dransfield I, Gregory C, Haslett C (2002) A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2(12):965–975. doi:10.1038/nri957 PubMedCrossRef

110.

Takemura Y, Ouchi N, Shibata R, Aprahamian T, Kirber MT, Summer RS, Kihara S, Walsh K (2007) Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Investig 117(2):375–386. doi:10.1172/JCI29709 PubMedPubMedCentralCrossRef

111.

Fantuzzi G (2008) Adiponectin and inflammation: consensus and controversy. J Allergy Clin Immunol 121(2):326–330. doi:10.1016/j.jaci.2007.10.018 PubMedCrossRef

112.

Tomizawa A, Hattori Y, Kasai K (2009) Induction of gene expression in response to globular adiponectin in vascular endothelial cells. Life Sci 85(11–12):457–461. doi:10.1016/j.lfs.2009.07.012 PubMedCrossRef

113.

Ehling A, Schaffler A, Herfarth H, Tarner IH, Anders S, Distler O, Paul G, Distler J, Gay S, Scholmerich J, Neumann E, Muller-Ladner U (2006) The potential of adiponectin in driving arthritis. J Immunol 176(7):4468–4478PubMedCrossRef

114.

Heliovaara MK, Teppo AM, Karonen SL, Tuominen JA, Ebeling P (2006) Improved glycaemia in type 1 diabetes results in decreased levels of soluble adhesion molecules with no change in serum adiponectin or most acute phase proteins. Exp Clin Endocrinol Diabetes 114(6):295–300. doi:10.1055/s-2006-924265 PubMedCrossRef

115.

Kirdar S, Serter M, Ceylan E, Sener AG, Kavak T, Karadag F (2009) Adiponectin as a biomarker of systemic inflammatory response in smoker patients with stable and exacerbation phases of chronic obstructive pulmonary disease. Scand J Clin Lab Invest 69(2):219–224. doi:10.1080/00365510802474400 PubMedCrossRef

116.

Miller M, Pham A, Cho JY, Rosenthal P, Broide DH (2010) Adiponectin-deficient mice are protected against tobacco-induced inflammation and increased emphysema. Am J Physiol Lung Cell Mol Physiol 299(6):L834–L842. doi:10.1152/ajplung.00326.2009 PubMedPubMedCentralCrossRef

117.

Ho YL, Lin YH, Lee CM, Hsu RB, Ting HT, Chou NK, Chao CL, Wang SS, Hsu HC, Chen MF (2009) Prognostic significance of adipocytokines and extracellular matrix activity in heart failure patients with high B-type natriuretic peptide. Clin Biochem 42(13–14):1407–1412. doi:10.1016/j.clinbiochem.2009.06.013 PubMedCrossRef

118.

Cheng X, Folco EJ, Shimizu K, Libby P (2012) Adiponectin induces pro-inflammatory programs in human macrophages and CD4⁺ T cells. J Biol Chem 287(44):36896–36904. doi:10.1074/jbc.M112.409516 PubMedPubMedCentralCrossRef

119.

Park PH, McMullen MR, Huang H, Thakur V, Nagy LE (2007) Short-term treatment of RAW264.7 macrophages with adiponectin increases tumor necrosis factor-alpha (TNF-alpha) expression via ERK1/2 activation and Egr-1 expression: role of TNF-alpha in adiponectin-stimulated interleukin-10 production. J Biol Chem 282(30):21695–21703. doi:10.1074/jbc.M701419200 PubMedPubMedCentralCrossRef

120.

Cavusoglu E, Chopra V, Battala V, Ruwende C, Yanamadala S, Eng C, Pinsky DJ, Marmur JD (2008) Baseline plasma adiponectin levels as a predictor of left ventricular systolic dysfunction in patients referred for coronary angiography. Am J Cardiol 101(8):1073–1078. doi:10.1016/j.amjcard.2007.12.008 PubMedCrossRef

121.

Celik T, Yaman H (2010) Elevated adiponectin levels in patients with chronic heart failure: an independent predictor of mortality or a marker of cardiac cachexia? Int J Cardiol 144(2):319–320. doi:10.1016/j.ijcard.2009.03.006 PubMedCrossRef

122.

Dieplinger B, Gegenhuber A, Poelz W, Haltmayer M, Mueller T (2009) Prognostic value of increased adiponectin plasma concentrations in patients with acute destabilized heart failure. Clin Biochem 42(10–11):1190–1193. doi:10.1016/j.clinbiochem.2009.02.023 PubMedCrossRef

123.

Adamopoulos S, Coats AJ, Brunotte F, Arnolda L, Meyer T, Thompson CH, Dunn JF, Stratton J, Kemp GJ, Radda GK et al (1993) Physical training improves skeletal muscle metabolism in patients with chronic heart failure. J Am Coll Cardiol 21(5):1101–1106PubMedCrossRef

124.

Van Berendoncks AM, Beckers P, Hoymans VY, Possemiers N, Coenen S, Elseviers MM, Vrints CJ, Conraads VM (2011) beta-blockers modify the prognostic value of adiponectin in chronic heart failure. Int J Cardiol 150(3):296–300. doi:10.1016/j.ijcard.2010.04.039 PubMedCrossRef

125.

Isobe T, Saitoh S, Takagi S, Takeuchi H, Chiba Y, Katoh N, Shimamoto K (2005) Influence of gender, age and renal function on plasma adiponectin level: the Tanno and Sobetsu study. Eur J Endocrinol 153(1):91–98. doi:10.1530/eje.1.01930 PubMedCrossRef

126.

Van Berendoncks AM, Garnier A, Beckers P, Hoymans VY, Possemiers N, Fortin D, Van Hoof V, Dewilde S, Vrints CJ, Ventura-Clapier R, Conraads VM (2011) Exercise training reverses adiponectin resistance in skeletal muscle of patients with chronic heart failure. Heart 97(17):1403–1409. doi:10.1136/hrt.2011.226373 PubMedCrossRef

127.

Dieplinger B, Gegenhuber A, Haltmayer M, Mueller T (2009) Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. Heart 95(18):1508–1513. doi:10.1136/hrt.2009.170696 PubMedCrossRef

128.

Fu M, Zhou J, Qian J, Jin X, Zhu H, Zhong C, Fu M, Zou Y, Ge J (2012) Adiponectin through its biphasic serum level is a useful biomarker during transition from diastolic dysfunction to systolic dysfunction—an experimental study. Lipids Health Dis 11:106. doi:10.1186/1476-511X-11-106 PubMedPubMedCentralCrossRef

129.

Risch L, Saely C, Hoefle G, Rein P, Langer P, Gouya G, Marte T, Aczel S, Drexel H (2007) Relationship between glomerular filtration rate and the adipokines adiponectin, resistin and leptin in coronary patients with predominantly normal or mildly impaired renal function. Clin Chim Acta 376(1–2):108–113. doi:10.1016/j.cca.2006.07.026 PubMedCrossRef

130.

Tentolouris N, Doulgerakis D, Moyssakis I, Kyriaki D, Makrilakis K, Kosmadakis G, Stamatiadis D, Katsilambros N, Stathakis C (2004) Plasma adiponectin concentrations in patients with chronic renal failure: relationship with metabolic risk factors and ischemic heart disease. Horm Metab Res 36(10):721–727. doi:10.1055/s-2004-826022 PubMedCrossRef

131.

Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y (2002) Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13(1):134–141PubMed

Titel: The evolving role of adiponectin as an additive biomarker in HFrEF
verfasst von: Tahnee Sente
Andreas Gevaert
An Van Berendoncks
Christiaan J. Vrints
Vicky Y. Hoymans
Publikationsdatum: 01.08.2016
Verlag: Springer US
Erschienen in: Heart Failure Reviews / Ausgabe 6/2016
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-016-9578-z

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The evolving role of adiponectin as an additive biomarker in HFrEF

Abstract

Neu im Fachgebiet Kardiologie

Die „Zehn Gebote“ des Endokarditis-Managements

Strenge Blutdruckeinstellung lohnt auch im Alter noch

Frauen bekommen seltener eine intensive Statintherapie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

Update Kardiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

The treatment gap in patients with chronic systolic heart failure: a systematic review of evidence-based prescribing in practice

Cardiac contractility modulation: a novel approach for the treatment of heart failure

Personalised computational cardiology: Patient-specific modelling in cardiac mechanics and biomaterial injection therapies for myocardial infarction

Myocardial transcription factors in diastolic dysfunction: clues for model systems and disease

Recent advances in the noninvasive strategies of cardiac amyloidosis

Zebrafish models of cardiovascular disease

Neu im Fachgebiet Kardiologie

Die „Zehn Gebote“ des Endokarditis-Managements

Strenge Blutdruckeinstellung lohnt auch im Alter noch

Frauen bekommen seltener eine intensive Statintherapie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

Update Kardiologie